Search

Your search keyword '"F. Bonnet"' showing total 619 results
Start Over Author "F. Bonnet" Database OpenAIRE
619 results on '"F. Bonnet"'

2. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

Author

Bernard Surial, Adrià Ramírez Mena, Marie Roumet, Andreas Limacher, Colette Smit, Olivier Leleux, Amanda Mocroft, Marc van der Valk, Fabrice Bonnet, Lars Peters, Jürgen K. Rockstroh, Huldrych F. Günthard, Annalisa Berzigotti, Andri Rauch, Gilles Wandeler, I. Abela, K. Aebi-Popp, A. Anagnostopoulos, M. Battegay, E. Bernasconi, D.L. Braun, H.C. Bucher, A. Calmy, M. Cavassini, A. Ciuffi, G. Dollenmaier, M. Egger, L. Elzi, J. Fehr, J. Fellay, H. Furrer, C.A. Fux, H.F. Günthard, A. Hachfeld, D. Haerry, B. Hasse, H.H. Hirsch, M. Hoffmann, I. Hösli, M. Huber, D. Jackson-Perry, C.R. Kahlert, L. Kaiser, O. Keiser, T. Klimkait, R.D. Kouyos, H. Kovari, K. Kusejko, N. Labhardt, K. Leuzinger, Martinez de Tejada B, C. Marzolini, K.J. Metzner, N. Müller, J. Nemeth, D. Nicca, J. Notter, P. Paioni, G. Pantaleo, M. Perreau, A. Rauch, L. Salazar-Vizcaya, P. Schmid, R. Speck, M. Stöckle, P. Tarr, A. Trkola, G. Wandeler, M. Weisser, S. Yerly, M. van der Valk, S.E. Geerlings, A. Goorhuis, V.C. Harris, J.W. Hovius, B. Lempkes, F.J.B. Nellen, T. van der Poll, J.M. Prins, V. Spoorenberg, M. van Vugt, W.J. Wiersinga, F.W.M.N. Wit, C. Bruins, J. van Eden, I.J. Hylkema-van den Bout, A.M.H. van Hes, F.J.J. Pijnappel, S.Y. Smalhout, A.M. Weijsenfeld, N.K.T. Back, B. Berkhout, M.T.E. Cornelissen, R. van Houdt, M. Jonges, S. Jurriaans, C.J. Schinkel, K.C. Wolthers, H.L. Zaaijer, E.J.G. Peters, M.A. van Agtmael, R.S. Autar, M. Bomers, K.C.E. Sigaloff, M. Heitmuller, L.M. Laan, M. van den Berge, A. Stegeman, S. Baas, L. Hage de Looff, A. van Arkel, J. Stohr, B. Wintermans, M.J.H. Pronk, H.S.M. Ammerlaan, E.S. de Munnik, B. Deiman, A.R. Jansz, V. Scharnhorst, J. Tjhie, M.C.A. Wegdam, A. van Eeden, E. Hoornenborg, J. Nellen, W. Alers, L.J.M. Elsenburg, H. Nobel, M.E.E. van Kasteren, M.A.H. Berrevoets, A.E. Brouwer, B.A.F.M. de Kruijf-van de Wiel, A. Adams, M. Pawels-van Rijkevoorsel, A.G.M. Buiting, J.L. Murck, C. Rokx, A.A. Anas, H.I. Bax, E.C.M. van Gorp, M. de Mendonça Melo, E. van Nood, J.L. Nouwen, B.J.A. Rijnders, C.A.M. Schurink, L. Slobbe, T.E.M.S. de Vries-Sluijs, N. Bassant, J.E.A. van Beek, M. Vriesde, L.M. van Zonneveld, J. de Groot, J.J.A. van Kampen, M.P.G. Koopmans, J.C. Rahamat-Langendoen, J. Branger, R.A. Douma, A.S. Cents-Bosma, C.J.H.M. Duijf-van de Ven, E.F. Schippers, C. van Nieuwkoop, J. Geilings, S. van Winden, G. van der Hut, N.D. van Burgel, E.M.S. Leyten, L.B.S. Gelinck, F. Mollema, G.S. Wildenbeest, T. Nguyen, P.H.P. Groeneveld, J.W. Bouwhuis, A.J.J. Lammers, A.G.W. van Hulzen, S. Kraan, M.S.M. Kruiper, G.L. van der Bliek, P.C.J. Bor, S.B. Debast, G.H.J. Wagenvoort, A.H.E. Roukens, M.G.J. de Boer, H. Jolink, M.M.C. Lambregts, H. Scheper, W. Dorama, N. van Holten, E.C.J. Claas, E. Wessels, J.G. den Hollander, R. El Moussaoui, K. Pogany, C.J. Brouwer, D. Heida-Peters, E. Mulder, J.V. Smit, D. Struik-Kalkman, T. van Niekerk, O. Pontesilli, C. van Tienen, S.H. Lowe, A.M.L. Oude Lashof, D. Posthouwer, M.E. van Wolfswinkel, R.P. Ackens, K. Burgers, M. Elasri, J. Schippers, T.R.A. Havenith, M. van Loo, M.G.A. van Vonderen, L.M. Kampschreur, M.C. van Broekhuizen, null S, null Faber, A. Al Moujahid, G.J. Kootstra, C.E. Delsing, M. van der Burg-van de Plas, L. Scheiberlich, W. Kortmann, G. van Twillert, R. Renckens, J. Wagenaar, D. Ruiter-Pronk, F.A. van Truijen-Oud, J.W.T. Cohen Stuart, M. Hoogewerf, W. Rozemeijer, J.C. Sinnige, K. Brinkman, G.E.L. van den Berk, K.D. Lettinga, M. de Regt, W.E.M. Schouten, J.E. Stalenhoef, J. Veenstra, S.M.E. Vrouenraets, H. Blaauw, G.F. Geerders, M.J. Kleene, M. Knapen, M. Kok, I.B. van der Meché, A.J.M. Toonen, S. Wijnands, E. Wttewaal, D. Kwa, T.J.W. van de Laar, R. van Crevel, K. van Aerde, A.S.M. Dofferhoff, S.S.V. Henriet, H.J.M. ter Hofstede, J. Hoogerwerf, O. Richel, M. Albers, K.J.T. Grintjes-Huisman, M. de Haan, M. Marneef, M. McCall, D. Burger, E.H. Gisolf, M. Claassen, R.J. Hassing, G. ter Beest, P.H.M. van Bentum, M. Gelling, Y. Neijland, C.M.A. Swanink, M. Klein Velderman, S.F.L. van Lelyveld, R. Soetekouw, L.M.M. van der Prijt, J. van der Swaluw, J.S. Kalpoe, A. Wagemakers, A. Vahidnia, F.N. Lauw, D.W.M. Verhagen, M. van Wijk, W.F.W. Bierman, M. Bakker, R.A. van Bentum, M.A. van den Boomgaard, J. Kleinnijenhuis, E. Kloeze, A. Middel, D.F. Postma, H.M. Schenk, Y. Stienstra, M. Wouthuyzen-Bakker, A. Boonstra, H. de Jonge, M.M.M. Maerman, D.A. de Weerd, K.J. van Eije, M. Knoester, C.C. van Leer-Buter, H.G.M. Niesters, null T.Mudrikova, R.E. Barth, A.H.W. Bruns, P.M. Ellerbroek, M.P.M. Hensgens, J.J. Oosterheert, E.M. Schadd, A. Verbon, B.J. van Welzen, H. Berends, B.M.G. Griffioen-van Santen, I. de Kroon, F.M. Verduyn Lunel, A.M.J. Wensing, S. Zaheri, A.C. Boyd, D.O. Bezemer, A.I. van Sighem, C. Smit, M.M.J. Hillebregt, T.J. Woudstra, T. Rutkens, D. Bergsma, N.M. Brétin, K.J. Lelivelt, L. van de Sande, K.M. Visser.S.T. van der Vliet, F. Paling, L.G.M. de Groot-Berndsen, M. van den Akker, R. Alexander, Y. Bakker, A. El Berkaoui, M. Bezemer-Goedhart, E.A. Djoechro, M. Groters, L.E. Koster, C.R.E. Lodewijk, E.G.A. Lucas, L. Munjishvili, B.M. Peeck, C.M.J. Ree, R. Regtop, A.F. van Rijk, Y.M.C. Ruijs-Tiggelman, P.P. Schnörr, M.J.C. Schoorl, E.M. Tuijn, D.P. Veenenberg, E.C.M. Witte, I. Karpov, M. Losso, J. Lundgren, J. Rockstroh, I. Aho, L.D. Rasmussen, P. Novak, C. Pradier, N. Chkhartishvili, R. Matulionyte, C. Oprea, J.D. Kowalska, J. Begovac, J.M. Miró, G. Guaraldi, R. Paredes, L. Peters, J.F. Larsen, B. Neesgaard, N. Jaschinski, O. Fursa, D. Raben, D. Kristensen, A.H. Fischer, S.K. Jensen, T.W. Elsing, M. Gardizi, A. Mocroft, A. Phillips, J. Reekie, A. Cozzi-Lepri, A. Pelchen-Matthews, A. Roen, E.S. Tusch, W. Bannister, P. Bellecave, P. Blanco, F. Bonnet, S. Bouchet, D. Breilh, C. Cazanave, S. Desjardin, V. Gaborieau, A. Gimbert, M. Hessamfar, L. Lacaze-Buzy, D. Lacoste, M.E. Lafon, E. Lazaro, O. Leleux, F. Le Marec, G. Le Moal, D. Malvy, L. Marchand, P. Mercié, D. Neau, I. Pellegrin, A. Perrier, V. Petrov-Sanchez, M.O. Vareil, L. Wittkop, N. Bernard, D. Bronnimann H. Chaussade, D. Dondia, P. Duffau, I. Faure, P. Morlat, E. Mériglier, F. Paccalin, E. Riebero, C. Rivoisy, M.A. Vandenhende, L. Barthod, F.A. Dauchy, A. Desclaux, M. Ducours, H. Dutronc, A. Duvignaud, J. Leitao, M. Lescure, D. Nguyen, T. Pistone, M. Puges, G. Wirth, C. Courtault, F. Camou, C. Greib, J.L. Pellegrin, E. Rivière, J.F. Viallard, Y. Imbert, M. Thierry-Mieg, P. Rispal, O. Caubet, H. Ferrand, S. Tchamgoué, S. Farbos, H. Wille, K. Andre, L. Caunegre, Y. Gerard, F. Osorio-Perez, I. Chossat, G. Iles, M. Labasse-Depis, F. Lacassin, A. Barret, B. Castan, J. Koffi, N. Rouanes, A. Saunier, J.B. Zabbe, G. Dumondin, G. Beraud, M. Catroux, M. Garcia, V. Giraud, J.P. Martellosio, F. Roblot, T. Pasdeloup, A. Riché, M. Grosset, S. Males, C. Ngo Bell, C. Carpentier, Virology P. Bellecave, C. Tumiotto, G. Miremeont-Salamé, D. Arma, G. Arnou, M.J. Blaizeau, P. Camps, M. Decoin, S. Delveaux, F. Diarra, L. Gabrea, S. Lawson-Ayayi, E. Lenaud, D. Plainchamps, A. Pougetoux, B. Uwamaliya, K. Zara, V. Conte, M. Gapillout, Internal medicine, VU University medical center, Medical Microbiology and Infection Prevention, AII - Infectious diseases, CCA - Cancer biology and immunology, AII - Inflammatory diseases, AMS - Rehabilitation & Development, APH - Quality of Care, Pulmonary medicine, ACS - Pulmonary hypertension & thrombosis, Ethics, Law & Medical humanities, APH - Methodology, Midwifery Science, Amsterdam Reproduction & Development (AR&D), Infectious diseases, APH - Digital Health, APH - Personalized Medicine, APH - Aging & Later Life, APH - Global Health, Global Health, APH - Health Behaviors & Chronic Diseases, Center of Experimental and Molecular Medicine, General Internal Medicine, AII - Cancer immunology, Landsteiner Laboratory, Cardiology, ACS - Heart failure & arrhythmias, Obstetrics and Gynaecology, ARD - Amsterdam Reproduction and Development, Microbes in Health and Disease (MHD), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Global Health in the Global South (GHiGS), Institut de Recherche pour le Développement (IRD)- Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Hepatitis B virus, model validation, Hepatology, liver neoplasms, risk prediction models, liver cirrhosis, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], risk assessment, 610 Medicine & health, hepatocellular carcinoma, HIV infection, tenofovir, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, 610 Medizin und Gesundheit
Abstract

Background & Aims: HBV coinfection is common among people living with HIV (PLWH) and is the most important cause of hepatocellular carcinoma (HCC). While risk prediction tools for HCC have been validated in patients with HBV monoinfection, they have not been evaluated in PLWH. Thus, we performed an external validation of PAGE-B in people with HIV/HBV coinfection.Methods: We included data on PLWH from four European cohorts who were positive for HBsAg and did not have HCC before starting tenofovir. We estimated the predictive performance of PAGE-B for HCC occurrence over 15 years in patients receiving tenofovir-containing antiretroviral therapy. Model discrimination was assessed after multiple imputation using Cox regression with the prognostic index as a covariate, and by calculating Harrell's c-index. Calibration was assessed by comparing our cumulative incidence with the PAGE-B derivation study using Kaplan-Meier curves.Results: In total, 2,963 individuals with HIV/HBV coinfection on tenofovir-containing antiretroviral therapy were included. PAGE-B was Conclusions: For individuals with HIV/HBV coinfection, PAGE-B is a valid tool to determine the need for HCC screening. Impact and implications: Chronic HBV infection is the most important cause of hepatocellular carcinoma (HCC) among people living with HIV. Valid risk prediction may enable better targeting of HCC screening efforts to high-risk individuals. We aimed to validate PAGE-B, a risk prediction tool that is based on age, sex, and platelets, in 2,963 individuals with HIV/HBV coinfection who received tenofovir-containing antiretroviral therapy. In the present study, PAGE-B showed good discrimination, adequate calibration, and a cut-off of

Published
2023
Full Text
View/download PDF

7. Auto-évaluation de professionnels de santé concernant la prise en charge des personnes trans dans un hôpital universitaire

Author

L. Vassal, D. Travers, Benoit Peyronnet, C. Ravel, Zineddine Khene, C. Richard, S. Aillet, Quentin Alimi, N. Morel-Journel, A. Guenego, Juliette Hascoet, F. Bonnet, N. Bertheuil, E. Duval, Lucas Freton, and Romain Mathieu

Subjects
03 medical and health sciences, 0302 clinical medicine, business.industry, Urology, 030232 urology & nephrology, Medicine, business, Humanities
Abstract

Resume Introduction Les personnes trans sont moins bien pris en charge par la communaute medicale que la population cisgenre probablement a cause d’un manque de connaissance, d’enseignement et de confort de la part des professionnels de sante. Le but de cette etude etait d’evaluer les connaissances et le confort ressentis par les professionnels de sante dans la prise en charge des personnes trans dans un centre hospitalo-universitaire (CHU) francais. Methodes Un auto-questionnaire a ete envoye par mail a des professionnels de sante travaillant dans des services habituellement impliques dans la prise en charge de personnes transgenres dans un CHU francais « non specialise » dans la transition hormono-chirurgicale trans. Le questionnaire comprenait des questions demographiques et des echelles de Likert concernant leur connaissance et leur confort ressentis dans la prise en charge des personnes trans. Les reponses des echelles de Likert de 7 degres etaient reparties selon des groupes « faible », « moyen » et « eleve » et celles de 5 degres etaient reparties selon des groupes « en faveur », « neutre » et « en defaveur ». Resultats Cent-deux (29 %) professionnels ont repondu au questionnaire. La moitie travaillaient en chirurgie (urologie, chirurgie plastique, gynecologie), 24 % travaillaient en medecine (endocrinologie, PMA, cytogenetique) et 26 % travaillaient en psychiatrie. La majorite (60,3 %) evaluaient leur niveau de connaissance comme « faible » et 39,7 % comme « moyen ». Seize pour cent evaluaient leur niveau de confort dans la prise en charge des trans comme « faible », 72,5 % comme « moyen » et 11,5 % comme « eleve ». Une majorite (77,5 %) etaient en faveur d’une prise en charge par la securite sociale de la transition hormonale, chirurgicale ou d’un soutien psychologique, 16,4 % etaient neutres et 6 % etaient en defaveur. Les sentiments concernant la transition hormono-chirurgicale etaient tres majoritairement (96,4 %) en faveur ou neutre et 91 % souhaitaient plus de formation. Conclusion Le manque de confort des professionnels de sante d’un CHU non specialise dans la prise en charge des personnes transgenres semble etre en rapport avec un manque de connaissance et de formation et non pas avec un desaccord concernant la necessite de l’offre de soins aux personnes transgenres. Niveau de preuve 3.

Published
2021
Full Text
View/download PDF

12. Stratégies innovantes de vaccination anti-pneumococcique par rapport au schéma standard chez les patients atteints de vascularites associées aux ANCA recevant du rituximab : essai contrôlé randomisé multicentrique (PNEUMOVAS)

Author

B. Terrier, L. Richert, G. Pugnet, O. Aumaître, O. Moranne, E. Diot, A. Karras, F. Bonnet, C. De Moreuil, E. Hachulla, T. Le Gallou, C. Lebas, F. Maurier, C. Rafat, M. Samson, J.F. Augusto, C. Janssen, T. Quéméneur, F. Batteux, and O. Launay

Subjects
Gastroenterology, Internal Medicine
Published
2022
Full Text
View/download PDF

14. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

Author

Fabienne Marcellin, Sylvie Brégigeon-Ronot, Clémence Ramier, Camelia Protopopescu, Camille Gilbert, Vincent Di Beo, Claudine Duvivier, Morgane Bureau-Stoltmann, Eric Rosenthal, Linda Wittkop, Dominique Salmon-Céron, Patrizia Carrieri, Philippe Sogni, Tangui Barré, D. Salmon, R. Usubillaga, P. Sogni, B. Terris, P. Tremeaux, C. Katlama, M.A. Valantin, H. Stitou, A. Simon, P. Cacoub, S. Nafissa, Y. Benhamou, F. Charlotte, Virologie: S. Fourati, I. Poizot-Martin, O. Zaegel, H. Laroche, C. Tamalet, G. Pialoux, J. Chas, P. Callard, F. Bendjaballah, C. Amiel, C. Le Pendeven, B. Marchou, L. Alric, K. Barange, S. Metivier, J. Selves, F. Larroquette, E. Rosenthal, null Infectiologie, A. Naqvi, V. Rio, J. Haudebourg, M.C. Saint-Paul, A. De Monte, V. Giordanengo, C. Partouche, O. Bouchaud, A. Martin, M. Ziol, Y. Baazia, V. Iwaka-Bande, A. Gerber, M. Uzan, A. Bicart-See, D. Garipuy, M.J. Ferro-Collados, null Virologie, F. Nicot, A. Gervais, Y. Yazdanpanah, H. Adle-Biassette, G. Alexandre, G. Peytavin, C. Lascoux-Combe, J.M. Molina, P. Bertheau, M.L. Chaix, C. Delaugerre, S. Maylin, K. Lacombe, J. Bottero, J. Krause, P.M. Girard, D. Wendum, P. Cervera, J. Adam, C. Viala, D. Vittecocq, C. Goujard, Y. Quertainmont, E. Teicher, C. Pallier, O. Lortholary, C. Duvivier, C. Rouzaud, J. Lourenco, F. Touam, C. Louisin, V. Avettand-Fenoel, E. Gardiennet, A. Mélard, D. Neau, A. Ochoa, E. Blanchard, S. Castet-Lafarie, C. Cazanave, D. Malvy, M. Dupon, H. Dutronc, F. Dauchy, L. Lacaze-Buzy, A. Desclaux, P. Bioulac-Sage, P. Trimoulet, S. Reigadas, P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, null J, F. Paccalin, C. Martell, M.C. Pertusa, M. Vandenhende, P. Mercié, T. Pistone, M.C. Receveur, M. Méchain, P. Duffau, C. Rivoisy, I. Faure, S. Caldato, P. Bellecave, C. Tumiotto, J.L. Pellegrin, J.F. Viallard, E. Lazzaro, C. Greib, D. Zucman, C. Majerholc, M. Brollo, E. Farfour, F. Boué, J. Polo Devoto, I. Kansau, V. Chambrin, C. Pignon, L. Berroukeche, R. Fior, V. Martinez, S. Abgrall, M. Favier, C. Deback, Y. Lévy, S. Dominguez, J.D. Lelièvre, A.S. Lascaux, G. Melica, E. Billaud, F. Raffi, C. Allavena, V. Reliquet, D. Boutoille, C. Biron, M. Lefebvre, N. Hall, S. Bouchez, A. Rodallec, L. Le Guen, C. Hemon, P. Miailhes, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L. Cotte, T. Ferry, T. Perpoint, J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, M. Amiri, F. Valour, C. Augustin-Normand, C. Scholtes, T.T. Le-Thi, L. Piroth, P. Chavanet, M. Duong Van Huyen, M. Buisson, A. Waldner-Combernoux, S. Mahy, A. Salmon Rousseau, C. Martins, H. Aumaître, S. Galim, F. Bani-Sadr, D. Lambert, Y. Nguyen, J.L. Berger, M. Hentzien, V. Brodard, D. Rey, M. Partisani, M.L. Batard, C. Cheneau, M. Priester, C. Bernard-Henry, E. de Mautort, P. Fischer, P. Gantner, S. Fafi-Kremer, F. Roustant, P. Platterier, I. Kmiec, L. Traore, S. Lepuil, S. Parlier, V. Sicart-Payssan, E. Bedel, S. Anriamiandrisoa, C. Pomes, M. Mole, C. Bolliot, P. Catalan, M. Mebarki, A. Adda-Lievin, P. Thilbaut, Y. Ousidhoum, F.Z. Makhoukhi, O. Braik, R. Bayoud, C. Gatey, M.P. Pietri, V. Le Baut, R. Ben Rayana, D. Bornarel, C. Chesnel, D. Beniken, M. Pauchard, S. Akel, C. Lions, A. Ivanova, A.-S. Ritleg, C. Debreux, L. Chalal, J. Zelie, H. Hue, A. Soria, M. Cavellec, S. Breau, A. Joulie, P. Fisher, S. Gohier, D. Croisier-Bertin, S. Ogoudjobi, C. Brochier, V. Thoirain-Galvan, M. Le Cam, L. Wittkop, L. Esterle, J. Izopet, L. Serfaty, V. Paradis, B. Spire, P. Carrieri, O. Zaegel-Faucher, L. Meyer, F. Boufassa, B. Autran, A.M. Roque, C. Solas, H. Fontaine, D. Costagliola, V. Petrov-Sanchez, A. Levier, null P. Carrieri, M. Chalouni, V. Conte, L. Dequae-Merchadou, M. Desvallées, C. Gilbert, S. Gillet, Q. Guillochon, C. Khan, R. Knight, F. Marcellin, L. Michel, M. Mora, C. Protopopescu, P. Roux, T. Barré, C. Ramier, A. Sow, V. Di Beo, and M. Bureau

Subjects
Hepatology, Gastroenterology, Internal Medicine, Immunology and Allergy
Abstract

A growing literature shows an improvement of chronic hepatitis C virus (HCV)-related depression after successful treatment with direct-acting antivirals. However, depression after HCV cure remains insufficiently documented in people living with HIV (PLWH) and HCV, a population with specific mental health challenges. This study aimed to (i) document the prevalence of moderate-to-severe depression (PHQ-9 score ≥10) across different age classes in HCV-cured PLWH; (ii) identify associated socio-behavioral correlates.Descriptive analyses were performed on data collected during a cross-sectional survey (February 2018 - May 2019) nested in a prospective, multicenter cohort of individuals living with HIV and HCV (ANRS CO13 HEPAVIH). Socio-behavioral correlates of moderate-to-severe depression were identified using logistic regression.Among the 398 HCV-cured individuals in the study sample (median age [IQR]: 56 [53-59] years; 73.1% men), 23.9% presented with moderate-to-severe depression (PHQ-9 score ≥10). Depressive symptom prevalence rates were as follows: anhedonia: 52.3%; feeling 'down' or feelings of hopelessness: 48.3%; sleeping problems: 65.7%; lack of energy: 70.3%; eating disorders: 51.2%; lack of self-esteem: 34.3%; difficulty concentrating: 34.9%; sluggishness (in movement and voice) or restlessness: 24.6%; suicidal ideation: 17.1%. No significant difference was detected across age classes. Female sex, unhealthy alcohol use, sedentary lifestyle, and unhealthy eating behaviors were associated with increased odds of moderate-to-severe depression.Depressive symptoms were common in this sample of HCV-cured PLWH. Unlike findings for the French general population, the prevalence of depression did not decrease with age class. Mental health remains a key issue for HIV-HCV-coinfected individuals, even after HCV cure, especially in women and in individuals with unhealthy behaviors.Despite potential improvements in mental health after successful treatment with direct-acting antivirals, many people living with HIV (PLWH) and hepatitis C virus (HCV) - even in older age classes - still face depressive symptoms after HCV cure. In this population, women and people reporting unhealthy alcohol use, sedentary lifestyle, or unhealthy eating behaviors are more prone to report depressive symptoms after HCV cure. Mental health and lifestyle-related issues should be integrated in a global care model for PLWH living with or having a history of hepatitis C.

Published
2022

16. Approche GABAergique de la dépression du post-partum : une revue critique translationnelle

Author

Caroline Dubertret, P. Duriez, F. Bonnet-Brilhault, Wissam El-Hage, J. Verbe, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), CCSD, Accord Elsevier, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), and GHU Paris Psychiatrie et Neurosciences

Subjects
[SDV]Life Sciences [q-bio], Neurostéroïdes, Allopregnanolone, Dépression du post-partum, 3. Good health, 030227 psychiatry, [SDV] Life Sciences [q-bio], GABA, 03 medical and health sciences, Psychiatry and Mental health, 0302 clinical medicine, Arts and Humanities (miscellaneous), Postpartum depression, Neurosteroid, Brexanolone
Abstract

International audience; Introduction: Prevalence of postpartum depression (PPD) ranges from 10 to 15 % of parturients. The impact of the PPD is major on the maternal bond and the health of both mother and child. Its physiopathological mechanisms appear to differ from other types of depression. Today, pharmacotherapy is based on nonspecific treatment, and recent therapeutic advances in this field require a comprehensive approach of the implication of the GABAergic system in the development of PPD. Neurosteroid levels during pregnancy and after parturition and the GABA-A-r modulation are thought to be involved in PPD.Objective: To evaluate if the GABAergic approach is relevant in postpartum depression management.Methods: We conducted a systematic review of literature based on the MEDLINE database with the following Medical Subject Headings (MeSH): "postpartum depression", "GABA", "ganaxolone", "brexanolone", "allopregnanolone", prior to September 2019. We selected articles in English: preclinical and clinical studies, literature review, observational and therapeutic studies.Results: Preclinical models (mouse and rat) show changes in GABAergic inhibition in the peripartum period and correlation between allopregnanolone and GABA-A-r plasticity. This plasticity in the peripartum period maintains levels of inhibition adapted despite increased neurosteroid levels. KO models for the GABA-A-r δ subunit develop depression and anxiety symptoms in the postpartum period, and a change in the expression of the gene coding for the GABA-R alpha-4 subunit was found. Artificial inhibition of progesterone metabolism during post-partum increased depression symptoms. GABAergic fluctuation seems to be interrelated with other systems such as those of oxytocins. A synthetic neurosteroid (SGE-516) was tested on mouse models of PPD, KO for δ-GABA-A-r or KCC2, and showed decreased depressive symptoms and better mothering. Clinical studies confirm neurosteroid fluctuation and changes in the GABAergic system during the peripartum period. Allopregnanolone is the neurosteroid the most studied in PPD, and it is elevated in the brain during the pregnancy. Studies disagree on the presence of significant differences in allopregnanolone plasma levels during pregnancy or postpartum between women with PPD or not. Women with a history of PPD have greater susceptibility to neurosteroid withdrawal. Imagery and genetical data also show a link between allopregnanolone and PPD. The GABA-A-r may not recover in time following a reduced number during pregnancy, and this mismatch between neurosteroid levels and their receptor may trigger PPD. Several randomized controlled trials investigated brexanolone administrated IV, a synthetic formulation of allopregnanolone, and demonstrated a rapid and well tolerated reduction in depressive symptoms. In March 2019 brexanolone obtained FDA approval in PPD indication under the name Zulresso. However, there are differences in the time of beginning of PPD, which could constitute different subgroups of this disease, and which physiopathology could respond to different mechanisms. Prenatal depression does not respond to a GABAergic approach, but women without any risk factor or previous mood disorder developing PPD in the weeks following childbirth could be particularly responsive to this kind of treatment.Conclusion: Disability to modulate GABA-A-r expression during pregnancy and restore its previous state after parturition appears to trigger PPD. The GABAergic system is a promising pharmacotherapy target. From preclinical to clinical studies for about twenty years the GABAergic system has been incriminated and targeted in this challenging mental disease.

Published
2020
Full Text
View/download PDF

20. Les mutations d’ARMC5 et KDM1A sont associées à des profils différentiels d’expression de récepteurs illégitimes dans l’hyperplasie macronodulaire bilatérale des surrénales

Author

L. Bouys, V. Florian, A. Vaczlavik, G. Giannone, A. Jouinot, R. Armignacco, I. Cavalcante, A. Berthon, E. Letouzé, P. Vaduva, M. Barat, F. Bonnet-Serrano, K. Perlemoine, C. Ribes, M. Sibony, M.O. North, S. Espiard, M. Haissaguerre, I. Tauveron, L. Guignat, L. Groussin, B. Dousset, M. Reincke, M. Fragoso, C. Stratakis, E. Pasmant, R. Libé, G. Assié, B. Ragazzon, and J. Bertherat

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, General Medicine
Published
2022
Full Text
View/download PDF

21. Female sex and angiotensin-converting enzyme (ace) insertion/deletion polymorphism amplify the effects of adiposity on blood pressure

Author

Martina Chiriacò, Domenico Tricò, Simone Leonetti, John R. Petrie, Beverley Balkau, Kurt Højlund, Zoltan Pataky, Peter M Nilsson, Andrea Natali, R.J. Heine, J. Dekker, S. de Rooij, G. Nijpels, W. Boorsma, A. Mitrakou, S. Tournis, K. Kyriakopoulou, P. Thomakos, N. Lalic, K. Lalic, A. Jotic, L. Lukic, M. Civcic, J. Nolan, T.P. Yeow, M. Murphy, C. DeLong, G. Neary, M.P. Colgan, M. Hatunic, T. Konrad, H. Böhles, S. Fuellert, F. Baer, H. Zuchhold, A. Golay, E. Harsch Bobbioni, V. Barthassat, V. Makoundou, T.N.O. Lehmann, T. Merminod, C. Perry, F. Neary, C. MacDougall, K. Shields, L. Malcolm, M. Laakso, U. Salmenniemi, A. Aura, R. Raisanen, U. Ruotsalainen, T. Sistonen, M. Laitinen, H. Saloranta, S.W. Coppack, N. McIntosh, J. Ross, L. Pettersson, P. Khadobaksh, M. Laville, F. Bonnet, A. Brac de la Perriere, C. Louche-Pelissier, C. Maitrepierre, J. Peyrat, S. Beltran, A. Serusclat, R. Gabriel, E.M. Sánchez, R. Carraro, A. Friera, B. Novella, P. Nilsson, M. Persson, G. Östling, O. Melander, P. Burri, P.M. Piatti, L.D. Monti, E. Setola, E. Galluccio, F. Minicucci, A. Colleluori, M. Walker, I.M. Ibrahim, M. Jayapaul, D. Carman, C. Ryan, K. Short, Y. McGrady, D. Richardson, H. Beck-Nielsen, P. Staehr, V. Vestergaard, C. Olsen, L. Hansen, G.B. Bolli, F. Porcellati, C. Fanelli, P. Lucidi, F. Calcinaro, A. Saturni, E. Ferrannini, E. Muscelli, S. Pinnola, M. Kozakova, A. Casolaro, B.D. Astiarraga, G. Mingrone, C. Guidone, A. Favuzzi, P. Di Rocco, C. Anderwald, M. Bischof, M. Promintzer, M. Krebs, M. Mandl, A. Hofer, A. Luger, W. Waldhäusl, M. Roden, J.M. Dekker, A. Mari, J. Petrie, P. Gaffney, G. Boran, A. Kok, S. Patel, A. Gastaldelli, D. Ciociaro, M.T. Guillanneuf, L. Mhamdi, L. Landucci, S. Hills, L. Mota, G. Pacini, C. Cavaggion, A. Tura, and S.A. Hills

Subjects
Adult, Male, medicine.medical_specialty, Genotype, Blood Pressure, Peptidyl-Dipeptidase A, Polymorphism, Single Nucleotide, Body Mass Index, angiotensin-converting enzyme, Sex Factors, INDEL Mutation, Polymorphism (computer science), Internal medicine, Internal Medicine, Sex characteristics, Medicine, Insertion deletion, Humans, Genetic Predisposition to Disease, Body mass index, Adiposity, biology, business.industry, Female sex, Angiotensin-converting enzyme, Middle Aged, Pathophysiology, Endocrinology, Blood pressure, Hypertension, biology.protein, Waist circumference, Female, sex characteristics, Waist Circumference, business, adiposity, blood pressure, body mass index, waist circumference
Abstract

The pathophysiological link between adiposity and blood pressure is not completely understood, and evidence suggests an influence of sex and genetic determinants. We aimed to identify the relationship between adiposity and blood pressure, independent of a robust set of lifestyle and metabolic factors, and to examine the modulating role of sex and Angiotensin-Converting Enzyme (ACE) insertion/deletion (I/D) polymorphisms. In the Relationship Between Insulin Sensitivity and Cardiovascular Disease (RISC) study cohort, 1211 normotensive individuals, aged 30 to 60 years and followed-up after 3.3 years, were characterized for lifestyle and metabolic factors, body composition, and ACE genotype. Body mass index (BMI) and waist circumference (WC) were independently associated with mean arterial pressure, with a stronger relationship in women than men (BMI: r =0.40 versus 0.30; WC: r =0.40 versus 0.30, both P ID and II ACE genotypes in both sexes ( P ACE genotype only in women ( P =0.03). A 5 cm larger WC at baseline increased the risk of developing hypertension at follow-up only in women (odds ratio, 1.56 [95% CI, 1.15–2.10], P =0.004) and in II genotype carriers (odds ratio, 1.87 [95% CI, 1.09–3.20], P =0.023). The hypertensive effect of adiposity is more pronounced in women and in people carrying the II variant of the ACE genotype, a marker of salt sensitivity.

Published
2022
Full Text
View/download PDF

24. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

Author

Fabienne Marcellin, Vincent Di Beo, Hugues Aumaitre, Marion Mora, Linda Wittkop, Claudine Duvivier, Camelia Protopopescu, Karine Lacombe, Laure Esterle, Cyril Berenger, Camille Gilbert, Olivier Bouchaud, Isabelle Poizot-Martin, Philippe Sogni, Dominique Salmon-Ceron, Patrizia Carrieri, D. Salmon, L. Wittkop, P. Sogni, L. Esterle, P. Trimoulet, J. Izopet, L. Serfaty, V. Paradis, B. Spire, P. Carrieri, M.A. Valantin, G. Pialoux, J. Chas, I. Poizot-Martin, K. Barange, A. Naqvi, E. Rosenthal, A. Bicart-See, O. Bouchaud, A. Gervais, C. Lascoux-Combe, C. Goujard, K. Lacombe, C. Duvivier, D. Neau, P. Morlat, F. Bani-Sadr, L. Meyer, F. Boufassa, B. Autran, A.M. Roque, C. Solas, H. Fontaine, D. Costagliola, L. Piroth, A. Simon, D. Zucman, F. Boué, P. Miailhes, E. Billaud, H. Aumaître, D. Rey, G. Peytavin, V. Petrov-Sanchez, D. Lebrasseur-Longuet, R. Usubillaga, B. Terris, P. Tremeaux, C. Katlama, H. Stitou, P. Cacoub, S. Nafissa, Y. Benhamou, F. Charlotte, S. Fourati, O. Zaegel, H. Laroche, C. Tamalet, P. Callard, F. Bendjaballah, C. Amiel, C. Le Pendeven, B. Marchou, L. Alric, S. Metivier, J. Selves, F. Larroquette, V. Rio, J. Haudebourg, M.C. Saint-Paul, A. De Monte, V. Giordanengo, C. Partouche, A. Martin, M. Ziol, Y. Baazia, V. Iwaka-Bande, A. Gerber, M. Uzan, D. Garipuy, M.J. Ferro-Collados, F. Nicot, Y. Yazdanpanah, H. Adle-Biassette, G. Alexandre, J.M. Molina, P. Bertheau, M.L. Chaix, C. Delaugerre, S. Maylin, J. Bottero, J. Krause, P.M. Girard, D. Wendum, P. Cervera, J. Adam, C. Viala, D. Vittecocq, Y. Quertainmont, E. Teicher, C. Pallier, O. Lortholary, C. Rouzaud, J. Lourenco, F. Touam, C. Louisin, V. Avettand-Fenoel, E. Gardiennet, A. Mélard, A. Ochoa, E. Blanchard, S. Castet-Lafarie, C. Cazanave, D. Malvy, M. Dupon, H. Dutronc, F. Dauchy, L. Lacaze-Buzy, A. Desclaux, P. Bioulac-Sage, S. Reigadas, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, J, F. Paccalin, C. Martell, M.C. Pertusa, M. Vandenhende, P. Mercié, T. Pistone, M.C. Receveur, M. Méchain, P. Duau, C. Rivoisy, I. Faure, S. Caldato, P. Bellecave, C. Tumiotto, J.L. Pellegrin, J.F. Viallard, E. Lazzaro, C. Greib, C. Majerholc, M. Brollo, E. Farfour, J. Polo Devoto, I. Kansau, V. Chambrin, C. Pignon, L. Berroukeche, R. Fior, V. Martinez, S. Abgrall, M. Favier, C. Deback, Y. Lévy, S. Dominguez, J.D. Lelièvre, A.S. Lascaux, G. Melica, F. Raffi, C. Allavena, V. Reliquet, D. Boutoille, C. Biron, M. Lefebvre, N. Hall, S. Bouchez, A. Rodallec, L. Le Guen, C. Hemon, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L. Cotte, T. Ferry, T. Perpoint, J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, M. Amiri, F. Valour, C. Augustin-Normand, C. Scholtes, T.T. Le-Thi, P. Chavanet, M. Duong Van Huyen, M. Buisson, A. Waldner-Combernoux, S. Mahy, R. Binois, A.L. Simonet-Lann, D. Croisier-Bertin, A. Salmon Rousseau, C. Martins, S. Galim, D. Lambert, Y. Nguyen, J.L. Berger, M. Hentzien, V. Brodard, M. Partisani, M.L. Batard, C. Cheneau, M. Priester, C. Bernard-Henry, E. de Mautort, P. Gantner et S Fafi-Kremer, F. Roustant, P. Platterier, I. Kmiec, L. Traore, S. Lepuil, S. Parlier, V. Sicart-Payssan, E. Bedel, S. Anriamiandrisoa, C. Pomes, M. Mole, C. Bolliot, P. Catalan, M. Mebarki, A. Adda-Lievin, P. Thilbaut, Y. Ousidhoum, F.Z. Makhoukhi, O. Braik, R. Bayoud, C. Gatey, M.P. Pietri, V. Le Baut, R. Ben Rayana, D. Bornarel, C. Chesnel, D. Beniken, M. Pauchard, S. Akel, C. Lions, A. Ivanova, A.-S. Ritleg, C. Debreux, L. Chalal, J. Zelie, H. Hue, A. Soria, M. Cavellec, S. Breau, A. Joulie, P. Fisher, S. Gohier, S. Ogoudjobi, C. Brochier, V. Thoirain-Galvan, M. Le Cam, M. Chalouni, V. Conte, L. Dequae-Merchadou, M. Desvallees, C. Gilbert, S. Gillet, R. Knight, T. Lemboub, F. Marcellin, L. Michel, M. Mora, C. Protopopescu, P. Roux, S. Tezkratt, T. Barré, M. Baudoin, M. Santos, V. Di Beo, M. Nishimwe, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Centre Hospitalier Saint Jean de Perpignan, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle de Santé publique [Bordeaux], CHU Bordeaux [Bordeaux], Service des Maladies infectieuses et tropicales [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de maladies infectieuses et tropicales [CHU Avicenne], Hôpital Avicenne [AP-HP], Université Paris 13 (UP13), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunobiologie des Cellules dendritiques, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Maladies infectieuses et tropicales [AP-HP Hôpital Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), This study was sponsored and funded by the French National Agency for Research on Aids and Viral Hepatitis (ANRS)., ANRS CO13 HEPAVIH Study Group : : D Salmon, L Wittkop, P Sogni, L Esterle, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, P Carrieri, M A Valantin, G Pialoux, J Chas, I Poizot-Martin, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, D Lebrasseur-Longuet, D Salmon, R Usubillaga, P Sogni, B Terris, P Tremeaux, C Katlama, M A Valantin, H Stitou, A Simon, P Cacoub, S Nafissa, Y Benhamou, F Charlotte, S Fourati, I Poizot-Martin, O Zaegel, H Laroche, C Tamalet, G Pialoux, J Chas, P Callard, F Bendjaballah, C Amiel, C Le Pendeven, B Marchou, L Alric, K Barange, S Metivier, J Selves, F Larroquette, E Rosenthal, A Naqvi, V Rio, J Haudebourg, M C Saint-Paul, A De Monte, V Giordanengo, C Partouche, O Bouchaud, A Martin, M Ziol, Y Baazia, V Iwaka-Bande, A Gerber, M Uzan, A Bicart-See, D Garipuy, M J Ferro-Collados, J Selves, F Nicot, A Gervais, Y Yazdanpanah, H Adle-Biassette, G Alexandre, G Peytavin, C Lascoux-Combe, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, K Lacombe, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, D Vittecocq, C Goujard, Y Quertainmont, E Teicher, C Pallier, O Lortholary, C Duvivier, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, E Gardiennet, A Mélard, D Neau, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, A Desclaux, P Bioulac-Sage, P Trimoulet, S Reigadas, P Morlat, D Lacoste, F Bonnet, N Bernard, M Hessamfar J, F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Mercié, D Malvy, T Pistone, M C Receveur, M Méchain, P Duau, C Rivoisy, I Faure, S Caldato, P Bioulac-Sage, P Trimoulet, S Reigadas, P Bellecave, C Tumiotto, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, P Bioulac-Sage, P Trimoulet, S Reigadas, D Zucman, C Majerholc, M Brollo, E Farfour, F Boué, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, S Abgrall, M Favier, C Deback, Y Lévy, S Dominguez, J D Lelièvre, A S Lascaux, G Melica, E Billaud, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, M Lefebvre, N Hall, S Bouchez, A Rodallec, L Le Guen, C Hemon, P Miailhes, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, F Valour, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, C Augustin-Normand, C Scholtes, T T Le-Thi, L Piroth, P Chavanet, M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, R Binois, A L Simonet-Lann, D Croisier-Bertin, A Salmon Rousseau, C Martins, H Aumaître, S Galim, F Bani-Sadr, D Lambert, Y Nguyen, J L Berger, M Hentzien, V Brodard, D Rey, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Gantner Et S Fafi-Kremer, F Roustant, P Platterier, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, S Anriamiandrisoa, C Pomes, F Touam, C Louisin, M Mole, C Bolliot, P Catalan, M Mebarki, A Adda-Lievin, P Thilbaut, Y Ousidhoum, F Z Makhoukhi, O Braik, R Bayoud, C Gatey, M P Pietri, V Le Baut, R Ben Rayana, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, S Caldato, C Lions, A Ivanova, A-S Ritleg, C Debreux, L Chalal, J Zelie, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, S Gohier, D Croisier-Bertin, S Ogoudjobi, C Brochier, V Thoirain-Galvan, M Le Cam, P Carrieri, M Chalouni, V Conte, L Dequae-Merchadou, M Desvallees, L Esterle, C Gilbert, S Gillet, R Knight, T Lemboub, F Marcellin, L Michel, M Mora, C Protopopescu, P Roux, B Spire, S Tezkratt, T Barré, M Baudoin, M Santos, V Di Beo, M Nishimwe, L Wittkop., Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Dupuis, Christine

Subjects
MESH: Antiviral Agents, medicine.medical_specialty, simeprevir + ribavirin (1). CI, [SDV]Life Sciences [q-bio], MEDLINE, sofosbuvir + simeprevir (3), HIV Infections, MESH: Patient Reported Outcome Measures, Antiviral Agents, sofosbuvir + ribavirin (4), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, MORPH3Eus, Humans, Patient Reported Outcome Measures, 030212 general & internal medicine, Antiviral treatment, ComputingMilieux_MISCELLANEOUS, MESH: Hepatitis C, MESH: Humans, Hepatology, Coinfection, business.industry, ledipasvir/sofosbuvir (49), ledipasvir/sofosbuvir + ribavirin (10), Hepatitis C, MESH: HIV Infections, Hepatitis C, Chronic, medicine.disease, 3. Good health, MESH: Coinfection, MESH: Hepatitis C, Chronic, [SDV] Life Sciences [q-bio], confidence interval, daclatasvir + sofosbuvir + ribavirin (5), 030211 gastroenterology & hepatology, Life study, business, ombitasvir/ paritaprevir/ritonavir + ribavirin (1), Direct acting, daclatasvir + sofosbuvir (32)
Abstract

International audience; No abstract available

Published
2020
Full Text
View/download PDF

25. Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients

Author

L. Piazza, C. Contin-Bordes, L. Tran, F. Bonnet, J. Lapoirie, M. E. Truchetet, Hôpital Saint-André, CHU Bordeaux [Bordeaux], Aquitaine Sciences Transfert, Immunology from Concept and Experiments to Translation (ImmunoConcept), Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Bordeaux

Subjects
MMP1, Metabolite, Pathogenesis, chemistry.chemical_compound, 0302 clinical medicine, Fibrosis, skin and connective tissue diseases, Chemokine CCL2, Skin, Multidisciplinary, integumentary system, Connective tissue disease, 3. Good health, 030220 oncology & carcinogenesis, Medicine, Matrix Metalloproteinase 1, Procollagen, medicine.drug, Cell biology, Science, Immunology, Primary Cell Culture, Irinotecan, Article, Collagen Type I, 03 medical and health sciences, Medical research, Rheumatology, medicine, Humans, RNA, Messenger, Active metabolite, 030203 arthritis & rheumatology, Scleroderma, Systemic, business.industry, Gene Expression Profiling, Fibroblasts, medicine.disease, Actins, Collagen Type I, alpha 1 Chain, Gene Expression Regulation, chemistry, Case-Control Studies, Cancer research, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Topoisomerase I Inhibitors, business, Camptothecin
Abstract

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by a microangiopathy and fibrosis of the skin and internal organs. No treatment has been proved to be efficient in case of early or advanced SSc to prevent or reduce fibrosis. There are strong arguments for a key role of topo-I in the pathogenesis of diffuse SSc. Irinotecan, a semisynthetic derivative of Camptothecin, specifically target topo-I. This study was undertaken to evaluate the effects of noncytotoxic doses of irinotecan or its active metabolite SN38 on collagen production in SSc fibroblasts. Dermal fibroblasts from 4 patients with SSc and 2 healthy donors were cultured in the presence or absence of irinotecan or SN38. Procollagen I release was determined by ELISA and expression of a panel of genes involved in fibrosis was evaluated by qRT-PCR. Subcytotoxic doses of irinotecan and SN38 caused a significant and dose-dependent decrease of the procollagen I production in dermal fibroblasts from SSc patients, respectively − 48 ± 3%, p p = 0.0097. Both irinotecan and SN38 led to a global downregulation of genes involved in fibrosis such as COL1A1, COL1A2, MMP1 and ACTA2 in dermal fibroblasts from SSc patients (respectively − 27; − 20.5; − 30.2 and − 30% for irinotecan and − 61; − 55; − 50 and − 54% for SN38). SN38 increased significantly CCL2 mRNA level (+ 163%). The inhibitory effect of irinotecan and its active metabolite SN38 on collagen production by SSc fibroblasts, which occurs through regulating the levels of expression of genes mRNA, suggests that topoisomerase I inhibitors may be effective in limiting fibrosis in such patients.

Published
2021
Full Text
View/download PDF

27. Avian frugivory rates at an abundant tree species are constant throughout the day and slightly influenced by weather conditions

Author

Olivier J. F. Bonnet, Maiara Vissoto, Rafael Antunes Dias, Jeferson Vizentin-Bugoni, and Gustavo Crizel Gomes

Subjects
0106 biological sciences, Abiotic component, education.field_of_study, Seed dispersal, Population, Foraging, food and beverages, Zoology, Biology, Generalist and specialist species, 010603 evolutionary biology, 01 natural sciences, 010605 ornithology, Frugivore, Common species, Temperate climate, education
Abstract

Birds, like most animals, are expected to adjust their foraging activity in response to biotic and abiotic variations to optimize energy intake and reduce costs associated with finding and ingesting food. This may lead to temporal variation in the exploitation of food resources, which has been investigated for birds of different feeding guilds but remains poorly understood for frugivorous species. Here, we tested whether the frugivory activity of birds on Schinus terebinthifolia trees varies throughout the day during the austral autumn and winter and whether variation is related to weather conditions. For two consecutive years, we quantified frugivory events for 304 h in 19 individuals of S. terebinthifolia observed across four time periods throughout the day. We found that the number of frugivory events was similar irrespective of the time period, both for the entire assemblage (all species pooled together) and for the most common species analyzed individually. We additionally found that frugivory activity was slightly influenced by temperature and wind. The lack of any effect of daytime period on fruit consumption may relate to the high and prolonged levels of fruit availability in S. terebinthifolia and the short photoperiod of the autumn–winter, which favors frequent feeding throughout the day. Such constant removal of fruits by a diverse assemblage of generalist fruit consumers probably enhances seed dispersal and may have important implications for the population dynamics of this abundant plant. Our results also demonstrate that data on avian frugivory in temperate, open-vegetation environments can be quantified throughout the entire daytime during the cold season without temporal bias, which has important methodological implications for studies on bird–plant interactions.

Published
2019
Full Text
View/download PDF

28. Analyse du profil de méthylation du sang total pour discriminer l’hypertension endocrine

Author

R. Armignacco, P.S. Reel, S. Reel, A. Jouinot, A. Septier, C. Gaspar, K. Perlemoine, C.K. Larsen, L. Bouys, L. Braun, A. Riester, M. Kroiss, F. Bonnet-Serrano, L. Amar, A. Blanchard, A.P. Gimenez-Roqueplo, A. Prejbisz, A. Januszewicz, P. Dobrowolski, E. Davies, S.M. Mackenzie, G.P. Rossi, L. Lenzini, F. Ceccato, C. Scaroni, P. Mulatero, T.A. Williams, A. Pecori, S. Monticone, F. Beuschlein, M. Reincke, M.C. Zennaro, J. Bertherat, E. Jefferson, and G. Assié

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, General Medicine
Published
2022
Full Text
View/download PDF

30. L’analyse des profils stéroïdiens sériques en HPLC-MSMS des patients traités par osilodrostat et métyrapone pour un syndrome de Cushing ACTH-dépendant montre des différences entre les deux inhibiteurs de CYP11B1 en routine clinique

Author

F. Bonnet-Serrano, J. Poirier, A. Vaczlavik, C. Laguillier-Morizot, B. Blanchet, L. Guignat, L. Bessiene, L. Bricaire, C. Zientek, C. Simonneau, L. Groussin, G. Assie, J. Guibourdenche, and J. Bertherat

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, General Medicine
Published
2022
Full Text
View/download PDF

33. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition

Author

P, Macquere, S, Orazio, F, Bonnet, N, Jones, V, Bubien, J, Chiron, D, Lafon, E, Barouk-Simonet, J, Tinat, L, Venat-Bouvet, P, Gesta, M, Longy, and N, Sevenet

Subjects
BRCA2 Protein, Ovarian Neoplasms, Incidence, Hereditary Breast and Ovarian Cancer Syndrome, Humans, Breast Neoplasms, Female, Genetic Predisposition to Disease, Ataxia Telangiectasia Mutated Proteins, Genetic Testing
Abstract

Pathogenic Variants (PV) in major cancer predisposition genes are only identified in approximately 10% of patients with Hereditary Breast and Ovarian Cancer (HBOC) syndrome. Next Generation Sequencing (NGS) leads to the characterization of incidental variants in genes other than those known to be associated with HBOC syndrome. The aim of this study was to determine if such incidental PV were specific to a phenotype. The detection rates of HBOC-associated and incidental PV in 1812 patients who underwent genetic testing were compared with rates in control groups FLOSSIES and ExAC. The rates of incidental PV in the PALB2, ATM and CHEK2 genes were significantly increased in the HBOC group compared to controls with, respective odds ratios of 15.2 (95% CI = 5.6-47.6), 9.6 (95% CI = 4.8-19.6) and 2.7 (95% CI = 1.3-5.5). Unsupervised Hierarchical Clustering on Principle Components characterized 3 clusters: by HBOC (P = 0.01); by ExAC and FLOSSIES (P = 0.01 and 0.02 respectively); and by HBOC, ExAC and FLOSSIES (P = 0.01, 0.04 and 0.04 respectively). Interestingly, PALB2 and ATM were grouped in the same statistical cluster defined by the HBOC group, whereas CHEK2 was in a different cluster. We identified co-occurrences of PV in ATM and BRCA genes and confirmed the Manchester Scoring System as a reliable PV predictor tool for BRCA genes but not for ATM or PALB2. This study demonstrates that ATM PV, and to a lesser extent CHEK2 PV, are associated with HBOC syndrome. The co-occurrence of ATM PV with BRCA PV suggests that such ATM variants are not sufficient alone to induce cancer, supporting a multigenism hypothesis.

Published
2021

34. [The BSE2 scale : A new clinical tool for the diagnostic of ASD within NDDs]

Author

F, Bonnet-Brilhault, S, Roux, R, Blanc, M, Gomot, P, Dansart, O, Rouvre, E, Houy-Durand, J, Malvy, and C, Barthélémy

Abstract

The behavioral summarized evaluation scales, the BSE and its revised version the BSE-R, were developed and validated in the 1980-1990s. The BSE-R is still used daily by clinical teams in France and foreign countries, and it is recommended by the French Health Authority (2018). Having taken into account knowledge improvement in neurodevelopment and autism spectrum disorder (ASD) and the importance of observation by relatives in ecological context, the second version of the BSE was developed. This paper presents the construction and the validation study of the second version of the behavioral summarized evaluation scale, the BSE2 and the BSE2-P rated by parents.Construct validity of the BSE2 scale has been studied in a population of 244 children and adolescents with ASD according to DSM-5 criteria, aged from 30 months to 18 years. Discriminant validity has been analyzed using a population of 86 patients of the same age, with neurodevelopmental disorder (NDD) without comorbidity of ASD.BSE2 comprises 30 items and is a two-dimensional scale as was BSE-R. Both dimensions, labelled "Interaction" (11 items) and "Modulation" (11 items), accounted for 41.7 % of the total variance. They describe autism severity and are in accordance with the two DSM-5 dimensions. Internal consistency (0.927 and 0.850 respectively) and inter-rater reliability (0.932 and 0.897 respectively) are good or excellent for both dimensions. Sensibility and specificity (0.758 and 0.767 respectively) range BSE2 among the tools with good psychometric properties. The parent version, BSE2-P, dedicated to ecological context is easily rated by parents.BSE2 scale for children and adolescents is a clinical tool with good psychometric properties. Its two-dimensional structure is in accordance with DSM-5 criteria. This scale covers all spectrum of ASD clinical forms in both children and adolescents. It can be used to identify ASD in complex neurodevelopmental disorders with several comorbidities and can help to distinguish autism symptomatology from other neurodevelopmental diagnoses. Furthermore, this scale allows to expand the rating context, involving parents to define and adjust the individualized therapeutic project. Thus the BSE2 is a valuable clinical tool for practitioners for both diagnosis and follow-up.

Published
2021

36. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study

Author

Bertrand Baussart, F. Bonnet, Stephan Gaillard, L. Cazabat, Anne Jouinot, Jérôme Bertherat, Anthony Dohan, Guillaume Assié, Luc Foubert, Michèle Bernier, Chiara Villa, and Marie-Laure Raffin-Sanson

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, Cohort Studies, Young Adult, Endocrinology, Microprolactinoma, Anterior pituitary, Dopamine, Internal medicine, medicine, Humans, Pituitary Neoplasms, Prolactinoma, Proportional hazards model, business.industry, General Medicine, Middle Aged, medicine.disease, Prolactin, Surgery, medicine.anatomical_structure, Treatment Outcome, Diabetes insipidus, Cohort, Dopamine Agonists, Neuroendoscopy, Female, business, Cohort study, medicine.drug, Follow-Up Studies
Abstract

Objective Microprolactinomas are currently treated with dopamine agonists. Outcome information on microprolactinoma patients treated by surgery is limited. This study reports the first large series of consecutive non-invasive microprolactinoma patients treated by pituitary surgery and evaluates the efficiency and safety of this treatment. Design Follow-up of a cohort of consecutive patients treated by surgery. Methods Between January 2008 and October 2020, 114 adult patients with pure microprolactinomas were operated on in a single tertiary expert neurosurgical department, using an endoscopic endonasal transsphenoidal approach. Eligible patients presented with a microprolactinoma with no obvious cavernous invasion on MRI. Prolactin was assayed before and after surgery. Disease-free survival was modeled using Kaplan–Meier representation. A cox regression model was used to predict remission. Results Median follow-up was 18.2 months (range: 2.8–155). In this cohort, 14/114 (12%) patients were not cured by surgery, including ten early surgical failures and four late relapses occurring 37.4 months (33–41.8) after surgery. From Kaplan–Meier estimates, 1-year and 5-year disease free survival was 90.9% (95% CI: 85.6–96.4%) and 81% (95% CI: 71.2–92.1%) respectively. The preoperative prolactinemia was the only significant preoperative predictive factor for remission (P < 0.05). No severe complication was reported, with no anterior pituitary deficiency after surgery, one diabetes insipidus, and one postoperative cerebrospinal fluid leakage properly treated by muscle plasty. Conclusions In well-selected microprolactinoma patients, pituitary surgery performed by an expert neurosurgical team is a valid first-line alternative treatment to dopamine agonists.

Published
2021

37. Experimental and numerical investigation of key microstructural features influencing the localization of plastic deformation in Fe-TiB2 metal matrix composite

Author

J. Genée, Nathalie Gey, Ricardo A. Lebensohn, Stéphane Berbenni, F. Bonnet, Laboratoire d'Etude des Microstructures et de Mécanique des Matériaux (LEM3), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM), Labex DAMAS, Université de Lorraine (UL), ArcelorMittal Maizières Research SA, ArcelorMittal, Los Alamos National Laboratory (LANL), and ANR-11-LABX-0008,DAMAS,Design des Alliages Métalliques pour Allègement des Structures(2011)

Subjects
plastic deformation, Materials science, 020502 materials, Mechanical Engineering, Metal matrix composite, metal matrix composites (MMCs), 02 engineering and technology, [SPI.MECA]Engineering Sciences [physics]/Mechanics [physics.med-ph], [SPI.MAT]Engineering Sciences [physics]/Materials, Full-Field FFT-based Numerical Simulations, Matrix (mathematics), [SPI]Engineering Sciences [physics], 0205 materials engineering, Mechanics of Materials, Electron Backscatter Diffraction (EBSD), Solid mechanics, Particle, Geometrically necessary dislocations, General Materials Science, Grain boundary, Dislocation, Deformation (engineering), Composite material, Electron backscatter diffraction
Abstract

International audience; A new generation of iron-based matrix composite reinforced by TiB2 particles was deformed in tension to investigate at a mesoscopic scale the localization of plastic deformation in relation with characteristic microstructural features of the composite (in particular, ferrite grain boundaries and particle/matrix interfaces). Large Electron Back-Scattered Diffraction (EBSD) maps with improved angular resolution were acquired to evaluate statistically the evolution of the geometrically-necessary dislocation (GND) density from the early stage of the deformation. GNDs were found to accumulate preferentially at matrix/particle interfaces with hot-spots located at the tips of elongated particles. Additional length-scale parameters derived from EBSD data evidenced the key influence of two main microstructural features: the particle morphology and the particle clustering. Finally, we present results of an advanced full-field micromechanical model that is best suited to capture these effects, based on an enhanced crystal plasticity elastoviscoplastic Fast Fourier Transform (EVP-FFT) formulation coupled with a phenomenological continuum Mesoscale Field Dislocation Mechanics (MFDM) theory. By taking the experimental TiB2 particle distribution into account, the model describes qualitatively the observed effect of particle morphological features on the heterogenous distribution of GNDs.

Published
2021
Full Text
View/download PDF

38. PROSPECT guidelines update for evidence-based pain management after prostatectomy for cancer

Author

Adrien Lemoine, Annemijn Witdouck, Hélène Beloeil, Francis Bonnet, E. Albrecht, H. Beloeil, F. Bonnet, A Delbos, S. Freys, A. Hill, G.P. Joshi, H. Kehlet, P. Lavand’homme, P. Lirk, D Lobo, E. Pogatzki-Zahn, N. Rawal, J. Raeder, A.R. Sauter, S. Schug, M. Van De Velde, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), PROSPECT is supported by an unrestricted grant from the European Society of Regional Anaesthesia and Pain Therapy (ESRA). In the past, PROSPECT had received unrestricted grants from Pfizer Inc. New York, NY, USA and Grunenthal, Aachen, Germany., Jonchère, Laurent, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
Laparoscopic surgery, Male, medicine.medical_specialty, Evidence-based practice, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Analgesic, MEDLINE, [SDV.CAN]Life Sciences [q-bio]/Cancer, Critical Care and Intensive Care Medicine, law.invention, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Randomized controlled trial, systematic review, law, Neoplasms, medicine, Humans, Pain Management, 030212 general & internal medicine, Abdominal Muscles, Prostatectomy, Pain, Postoperative, robot surgery, business.industry, Cancer, 030208 emergency & critical care medicine, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Nerve Block, General Medicine, medicine.disease, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, Surgery, [SDV] Life Sciences [q-bio], Anesthesiology and Pain Medicine, Systematic review, Prostatic surgery, Practice Guidelines as Topic, business, postoperative pain
Abstract

International audience; The aim of this review was to update the recommendations for optimal pain management after open and laparoscopic or robotic prostatectomy. Optimal pain management is known to influence postoperative recovery, but patients undergoing open radical prostatectomy typically experience moderate dynamic pain in the immediate postoperative day. Robot-assisted and laparoscopic surgery may be associated with decreased pain levels as opposed to open surgery. We performed a systematic review using Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) with PROcedure SPECific Postoperative Pain ManagemenT (PROSPECT) methodology. Randomised controlled trials (RCTs) published in the English language, from January 2015 until March 2020, assessing postoperative pain, using analgesic, anaesthetic and surgical interventions, were identified from MEDLINE, EMBASE and Cochrane Databases. Of the 1797 studies identified, 35 RCTs and 3 meta-analyses met our inclusion criteria. NSAIDs and COX-2 selective inhibitors proved to lower postoperative pain scores. Continuous intravenous lidocaine reduced postoperative pain scores during open surgery. Local wound infiltration showed positive results in open surgery. Bilateral transversus abdominis plane (TAP) block was performed at the end of surgery and lowered pain scores in robot-assisted procedures, but results were conflicting for open procedures. Basic analgesia for prostatic surgery should include paracetamol and NSAIDs or COX-2 selective inhibitors. TAP block should be recommended as the first-choice regional analgesic technique for laparoscopic/robotic radical prostatectomy. Intravenous lidocaine should be considered for open surgeries.

Published
2021
Full Text
View/download PDF

39. [Self-assessment of healthcare workers regarding the management of trans people in a university hospital]

Author

L, Freton, Z-E, Khene, C, Richard, R, Mathieu, Q, Alimi, E, Duval, L, Vassal, N, Bertheuil, S, Aillet, F, Bonnet, C, Ravel, A, Guenego, D, Travers, N, Morel-Journel, J, Hascoet, and B, Peyronnet

Subjects
Self-Assessment, Health Personnel, Humans, Delivery of Health Care, Transgender Persons, Hospitals
Abstract

Trans people face more barriers when seeking healthcare than the cisgender population probably due to a lack of knowledge, education and comfort of healthcare workers. The purpose of this study was to assess the knowledge and comfort felt by healthcare professionals in managing trans people in a French university hospital.A self-questionnaire was emailed to healthcare professionals working in departments usually involved in the care of trans people in a French university hospital "not specialized" in medical and surgical gender transition. The questionnaire included demographic questions and Likert scales regarding their knowledge and comfort in taking care of trans people. Responses on the 7-point Likert scales were categorized into "low", "medium" and "high" groups, and responses on the 5-point Likert scales were categorized into "in favour", "neutral" and "against" groups.One hundred and two (29%) healthcare professionals answered the questionnaire. Half worked in surgical departments (urology, plastic surgery, gynecology), 24% worked in medical departments (endocrinology, reproductive medicine, cytogenetics) and 26% worked in psychiatry. The majority (60.3%) rated their level of knowledge as "low" and 39.7% as "medium". Sixteen percent rated their level of comfort in managing trans people as "low", 72.5% as "medium" and 11.5% as "high". A majority (77.5%) were in favor of having the costs of gender transition care covered by the national health insurance system, 16.4% were neutral and 6% were against this idea. Feelings about surgical and hormonal gender transition were overwhelmingly (96.4%) in favour or neutral and 91% were willing to get more training and education to manage trans people.The lack of comfort felt by healthcare professionals in university hospital in managing trans people seems to be related to a lack of knowledge and training in that field and not to a disagreement with the need of transgender healthcare.3.

Published
2020

40. Particle interspacing effects on the mechanical behavior of a Fe–TiB2 metal matrix composite using FFT-based mesoscopic field dislocation mechanics

Author

Stéphane Berbenni, J. Genée, F. Bonnet, Nathalie Gey, Ricardo A. Lebensohn, Laboratoire d'Etude des Microstructures et de Mécanique des Matériaux (LEM3), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM), Labex DAMAS, Université de Lorraine (UL), Los Alamos National Laboratory (LANL), ArcelorMittal Maizières Research SA, and ArcelorMittal

Subjects
Materials science, Size effects, Crystal plasticity, 02 engineering and technology, Plasticity, lcsh:TA168, FFT, Continuum dislocation mechanics, 0203 mechanical engineering, [SPI.MECA.MEMA]Engineering Sciences [physics]/Mechanics [physics.med-ph]/Mechanics of materials [physics.class-ph], Geometrically necessary dislocations, Ceramic, Engineering (miscellaneous), Mesoscopic physics, Applied Mathematics, Metal matrix composite, Mechanics, 021001 nanoscience & nanotechnology, Microstructure, Computer Science Applications, 020303 mechanical engineering & transports, lcsh:Systems engineering, Modeling and Simulation, visual_art, visual_art.visual_art_medium, Hardening (metallurgy), Crystallite, Dislocation, 0210 nano-technology, lcsh:Mechanics of engineering. Applied mechanics, lcsh:TA349-359
Abstract

This paper presents an application to metal matrix composites (MMCs) of an enhanced elasto-viscoplastic Fast Fourier Transform (EVP-FFT) formulation coupled with a phenomenological continuum Mesoscale Field Dislocation Mechanics (MFDM) theory. Contrary to conventional crystal plasticity, which only accounts for plastic flow and hardening induced by statistically stored dislocations (SSDs), MFDM-EVP-FFT also describes the evolution of polarized geometrically necessary dislocation (GND) density and its effect on both plastic flow and hardening. Numerical results for a Fe–TiB2MMC made of a ferrite matrix (α-Fe) and elastic ceramic particles (TiB2) are presented. Full-field simulations are performed using synthetic periodic unit cells representative of the MMC, with single-crystalline and polycrystalline matrix, for different particle interspacing distances. A strong dependence of the predicted equivalent stress, cumulated plastic strain and GND density fields with particle interspacing distance is observed, in contrast with conventional crystal plasticity. Correlations between these mechanical fields and microstructural features, and their influence on local and global mechanical behavior are examined for the different MMC microstructures.

Published
2020
Full Text
View/download PDF

41. High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Pre-exposure Prophylaxis Trial

Author

C. Chapolard, L. Larmet, A. Becker, I. Madelaine, Rémy Choquet, M. Danet, Stéphane Morel, S. Parlier, N. Hall, E. Dalle, M Saouzanet, F. Clement, Y Saïdi, E. Rosenthal, M. Meunier, L. Zarka, C. Etienne, S. Rouby, Péchenot, J. Delgado, N. Dumon, S. Cousseau, M. Cavellec, M Suzan, Catherine Capitant, D. Ponscarme, B. Boissavy, S. Pailhes, Claire Pintado, Chloé Le Roy, C. Bernaud, J. Koffi, A. Djessima, P M Roger, A. Adda, Cécile Bébéar, B. Bonnet, F. Bonnet, H. Hue, Emmanuelle Netzer, Baptiste Demoulin, N Leturque, C. Gatey, Nadège Bourgeois-Nicolaos, F Euphrasie, Béatrice Berçot, C. Adouard-groslafeige, P. Penot, François Raffi, M. Godinot, R. Biekre, C. Monfort, Naoufel Mzoughi, F. Jeanblanc, A Cheret, Armelle Pasquet, Laurence Meyer, B Guillon, T. Huleux, Constance Delaugerre, J. Lambec, O. Leclanche, S. Bagge, R. Veron, Gilles Pialoux, G. Conort, B. Loze, S. le Nagat, F. Tolonin, Christian Chidiac, Sabine Pereyre, Nicolas Lorente, Berrebi, N. Mezreb, T. Cepitelli, A. Decouty, H. Melliez, S. Vandamme, A. Pansu, Michel Besnier, M. Colas, H. Bazus, Isabelle Charreau, W. Rozenbaum, X. Teruin, S. Huon, K. Moudachirou, Eric Senneville, J. Foucoin, L. Gilly, Foubert, P. Cornavin, Clotilde Rousseau, F. Lorho, J. Berdougo, S Fouéré, S. Breaud, C. Brochier, N. Mahjoub, G Cattin, J Binesse, and Jean-Michel Molina

Subjects
Microbiology (medical), Male, medicine.medical_specialty, HIV Infections, Mycoplasma genitalium, Azithromycin, Emtricitabine, Men who have sex with men, Pre-exposure prophylaxis, Sexual and Gender Minorities, Antibiotic resistance, Internal medicine, RNA, Ribosomal, 16S, medicine, Prevalence, Humans, Mycoplasma Infections, Homosexuality, Male, Doxycycline, biology, business.industry, Incidence (epidemiology), Drug Resistance, Microbial, biology.organism_classification, Infectious Diseases, Pre-Exposure Prophylaxis, business, medicine.drug
Abstract

Background Mycoplasma genitalium (MG) is an emerging pathogen among men who have sex with men (MSM) with raising rates of antibiotic resistance. This study assessed the prevalence and incidence of MG infection in MSM enrolled in the open-label phase of the ANRS IPERGAY trial with on-demand tenofovir disoproxil fumarate/emtricitabine for human immunodeficiency virus prevention and the impact of doxycycline post-exposure prophylaxis (PEP). Methods 210 subjects were tested at baseline and at 6 months by real-time PCR assays for MG detection in urine samples and oropharyngeal and anal swabs. Resistance to azithromycin (AZM), to fluoroquinolones (FQs), and to doxycycline was investigated in the French National Reference Center of Bacterial Sexually Transmitted Infections (STIs). Results The all-site prevalence of MG at baseline was 10.5% (6.3% in urine samples, 4.3% in anal swabs, 0.5% in throat swabs) and remained unchanged at 6 months whether or not PEP was used: 9.9% overall, 10.2% with PEP, 9.6% without. The overall rate of MG resistance (prevalent and incident cases) to AZM and FQs was 67.6% and 9.1%, respectively, with no difference between arms. An in vivo mutation of the MG 16S rRNA, which could be associated with tetracycline resistance, was observed in 12.5% of specimens tested. Conclusions The prevalence of MG infection among MSM on pre-exposure prophylaxis was high and its incidence was not decreased by doxycycline prophylaxis with a similar high rate of AZM and FQ resistance, raising challenging issues for the treatment of this STI and supporting current recommendations to avoid testing or treatment of asymptomatic MG infection.

Published
2020

42. One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort

Author

Manco, Melania, Mari, Andrea, Petrie, John, Mingrone, Geltrude, Balkau, Beverley, Amsterdam, for the EGIR-RISC study group., Heine, Rj, Dekker, J, S de Rooij, Nijpels, G, W Boorsma Athens, Greece:, A Mitrakou, Tournis, S, Kyriakopoulou, K, P Thomakos Belgrade, Serbia:, N Lalic, Lalic, K, Jotic, A, Lukic, L, M Civcic Dublin, Ireland:, J Nolan, Yeow, Tp, Murphy, M, Delong, C, Neary, G, Colgan, Mp, M Hatunic Frankfurt, Germany:, T Konrad, Böhles, H, Fuellert, S, Baer, F, H Zuchhold Geneva, Switzerland:, A Golay, E Harsch Bobbioni, Barthassat, V, Makoundou, V, Tno, Lehmann, T Merminod Glasgow, Scotland, UK: JR Petrie, Perry, C, Neary, F, Macdougall, C, Shields, K, L Malcolm Kuopio, Finland:, M Laakso, Salmenniemi, U, Aura, A, Raisanen, R, Ruotsalainen, U, Sistonen, T, Laitinen, M, H Saloranta London, England, UK: SW Coppack, Mcintosh, N, Ross, J, Pettersson, L, P Khadobaksh Lyon, France:, M Laville, F Bonnet (now Rennes), A Brac de la Perriere, Louche-Pelissier, C, Maitrepierre, C, Peyrat, J, Beltran, S, A Serusclat Madrid, Spain:, R Gabriel, Sánchez, Em, Carraro, R, Friera, A, B Novella Malmö, Sweden (1):, P Nilsson, Persson, M, G Östling (2):, O Melander, P Burri Milan, Italy: PM Piatti, Monti, Ld, Setola, E, Galluccio, E, Minicucci, F, A Colleluori Newcastle-upon-Tyne, Uk:, M Walker, Ibrahim, Im, Jayapaul, M, Carman, D, Ryan, C, Short, K, Mcgrady, Y, D Richardson Odense, Denmark:, H Beck-Nielsen, Staehr, P, Højlund, K, Vestergaard, V, Olsen, C, L Hansen Perugia, Italy: GB Bolli, Porcellati, F, Fanelli, C, Lucidi, P, Calcinaro, F, A Saturni Pisa, Italy:, E Ferrannini, Natali, A, Muscelli, E, Pinnola, S, Kozakova, M, Casolaro, A, BD Astiarraga Rome, Italy:, G Mingrone, Guidone, C, Favuzzi, A, P Di Rocco Vienna, Austria:, C Anderwald, Bischof, M, Promintzer, M, Krebs, M, Mandl, M, Hofer, A, Luger, A, Waldhäusl, W, and Roden, M

Subjects
Post-load glucose, Adult, Male, Blood Glucose, 0301 basic medicine, Diagnostic criteria, Endocrinology, Diabetes and Metabolism, Physiology, 030209 endocrinology & metabolism, Prediabetic State, 03 medical and health sciences, Endocrinology, 0302 clinical medicine, Research Letter, Internal Medicine, medicine, Humans, Prediabetes, Plasma glucose, Glucose tolerance test, Post-challenge glucose, Prediabetes phenotype, Progression, medicine.diagnostic_test, business.industry, Fasting, Female, Glucose Tolerance Test, Middle Aged, Settore MED/13 - ENDOCRINOLOGIA, Human physiology, medicine.disease, Diabetes and Metabolism, 030104 developmental biology, Cohort, business
Abstract

The affiliation details for Geltrude Mingrone are corrected below.

Published
2018
Full Text
View/download PDF

43. L’étude génomique de l’hyperplasie macronodulaire bilatérale primitive des surrénales (HMBPS) révèle 3 groupes aux caractéristiques clinico-pathologiques distinctes, un lié à ARMC5 et un deuxième à un nouveau gène responsable du syndrome de Cushing dépendant de l’alimentation : LSD1/KDM1A, étendant le spectre des causes génétiques du syndrome de Cushing surrénalien

Author

C. Ribes, Eric Pasmant, Maria Candida Barisson Villares Fragoso, Herve Lefebvre, Lucas Bouys, Igor Tauveron, Isadora Pontes Cavalcante, Karine Perlemoine, P. Vaduva, F. Bonnet, Marie-Odile North, M. Barat, G. Giannone, Mathilde Sibony, Eric Letouzé, Anna Vaczlavik, Roberta Armignacco, Martin Reincke, Jérôme Bertherat, F. Violon, A. Berthon, C. A. Stratakis, Guillaume Assié, L. Groussin, Anne Jouinot, R. Libe, Bertrand Dousset, Philippe Emy, Bruno Ragazzon, L. Guignat, Magalie Haissaguerre, and Stéphanie Espiard

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, General Medicine
Published
2021
Full Text
View/download PDF

44. Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study

Author

L. Willemin, Gilles Grateau, Pierre Quartier, S. Quere, Eric Hachulla, Isabelle Koné-Paut, F. Bonnet, O. Reigneau, Pascal Pillet, P. Le Blay, Olivier Fain, K. Stankovic-Stojanovic, and V. Despert

Subjects
030203 arthritis & rheumatology, Pediatrics, medicine.medical_specialty, business.industry, Cryopyrin-associated periodic syndrome, Retrospective cohort study, medicine.disease, 3. Good health, 03 medical and health sciences, Canakinumab, 0302 clinical medicine, Rheumatology, Quality of life, Cohort, Health care, medicine, Observational study, 030212 general & internal medicine, business, Psychosocial, medicine.drug
Abstract

Objective The ENVOL study was designed to assess the psychosocial impact of disease and therapy in a French cohort of cryopyrin-associated periodic syndromes (CAPS) patients (and caregivers) treated with canakinumab. Methods The ENVOL study was a multicenter, observational study of CAPS patients given ≥1 canakinumab dose. Data were collected before treatment, at 6 and 12 months afterward, and at the last visit. Patients and caregivers completed questionnaires assessing changes from the 12 months of pretreatment to 12 months prior to interview. Data were analyzed retrospectively. Results The study included 10 physicians and 68 patients (53 adults, 15 children). Sixty-five patients (95.6%) were still receiving canakinumab at the last visit (median 5 years after starting therapy). The mean ± SD score for patient-reported general health increased from 7 ± 2.9 before canakinumab to 2.7 ± 2.7 after treatment (P 40% of respondents. Caregivers spent a median of 3 versus 0.5 hours/week on care in the 12 months of pretreatment versus 12 months prior to interview (P

Published
2017
Full Text
View/download PDF

45. L’autisme : un trouble neuro-développemental précoce

Author

F Bonnet-Brilhault

Subjects
medicine.medical_specialty, business.industry, Psychological intervention, medicine.disease, behavioral disciplines and activities, Comorbidity, 3. Good health, 030227 psychiatry, 03 medical and health sciences, 0302 clinical medicine, Neurodevelopmental disorder, Autism spectrum disorder, mental disorders, Pediatrics, Perinatology and Child Health, medicine, Autism, Attention deficit hyperactivity disorder, Early childhood, Age of onset, business, Psychiatry, 030217 neurology & neurosurgery
Abstract

With approximately 67 million individuals affected worldwide, autism spectrum disorder (ASD) is the fastest growing neurodevelopmental disorder (United Nations, 2011), with a prevalence estimated to be 1/100. In France ASD affects approximately 600,000 individuals (from childhood to adulthood, half of whom are also mentally retarded), who thus have a major handicap in communication and in adapting to daily life, which leads autism to be recognized as a national public health priority. ASD is a neurodevelopmental disorder that affects several domains (i.e., socio-emotional, language, sensori-motor, executive functioning). These disorders are expressed early in life with an age of onset around 18 months. Despite evidence suggesting a strong genetic link with ASD, the genetic determinant remains unclear. The clinical picture is characterized by impairments in social interaction and communication and the presence of restrictive and repetitive behaviors (DSM-5, ICD-10). However, in addition to these two main dimensions there is significant comorbidity between ASD and other neurodevelopmental disorders such as attention deficit hyperactivity disorder or with genetic and medical conditions. One of the diagnostic features of ASD is its early emergence: symptoms must begin in early childhood for a diagnosis to be given. Due to brain plasticity, early interventions are essential to facilitate clinical improvement. Therefore, general practitioners and pediatricians are on the front line to detect early signs of ASD and to guide both medical explorations and early rehabilitation.

Published
2017
Full Text
View/download PDF

46. Lésions cutanées au cours d’une pneumopathie d’hypersensibilité aux bains bouillonnants : folliculites à Pseudomonas ?

Author

François Laurent, Marie-Anne Vandenhende, Philippe Morlat, J.-Y. Colin, L. Rolland, N. Sokolowsky, F. Bonnet, and Marie Beylot-Barry

Subjects
03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, 030212 general & internal medicine, Dermatology
Abstract

Resume Introduction Une atteinte interstitielle pulmonaire, une eruption cutanee et une elevation de l’enzyme de conversion peuvent suggerer d’autres diagnostics qu’une sarcoidose. Observation Un homme de 58 ans presentait depuis 2 ans une dyspnee avec une elevation du taux de l’enzyme de conversion et un syndrome interstitiel pulmonaire avec micronodules. Une sarcoidose etait evoquee. Une corticotherapie generale permettait l’amelioration de la dyspnee mais elle recidivait des l’arret. On notait des macules erythemateuses eczematiformes de la racine des membres, d’evolution fluctuante, avec histologiquement une folliculite aspecifique. L’identification d’une mycobacterie du complexe Mycobacterium avium (MAC) dans le lavage broncho-alveolaire faisait instaurer une antibiotherapie antimycobacterienne sans efficacite. La relecture de la tomodensitometrie pulmonaire et l’interrogatoire (utilisation quotidienne d’un jacuzzi depuis 7 ans) amenaient au diagnostic de pneumopathie d’hypersensibilite a MAC. Les lesions cutanees etaient, malgre leur aspect clinique eczematiforme, considerees comme des folliculites liees au jacuzzi (« hot tub folliculitis »). L’arret des bains bouillonnants et une breve corticotherapie generale permettaient la disparition des signes cliniques et une normalisation radiologique a 4 mois, sans recidive a 2 ans. Discussion Le « hot tub lung » est une pneumopathie d’hypersensibilite liee a la presence de MAC dans l’eau des jacuzzis. Elle regresse a l’arret de leur utilisation, sans autre traitement necessaire. La « hot tub folliculitis » liee a Pseudomonas aeruginosa se presente comme une eruption maculopapuleuse des zones couvertes (maillot) qui survient dans les 48 heures suivant une baignade et regresse en moins de deux semaines. Conclusion Notre cas est original par les atteintes pulmonaire et cutanee concomitantes liees a l’utilisation d’un jacuzzi, avec un mecanisme immuno-allergique pour la MAC et probablement infectieux pour les lesions cutanees.

Published
2017
Full Text
View/download PDF

47. Blocco del plesso cervicale

Author

F Bonnet, J P Guerin, A Theissen, L Ley-Ghiglione, and I Rouquette-Vincenti

Subjects
03 medical and health sciences, 0302 clinical medicine, 030202 anesthesiology, business.industry, Medicine, 030230 surgery, business, Humanities
Abstract

Il blocco del plesso cervicale ha come indicazione principale l’anestesia per la chirurgia carotidea. Consente, inoltre, la chirurgia minore del collo. La conoscenza dell’anatomia e essenziale. Gli spazi di diffusione delimitano tre tipi di blocco del plesso cervicale (BPC): superficiale, intermedio e profondo. Quest’ultimo puo essere ottenuto mediante una o piu iniezioni, con o senza neurostimolatore. Piu moderna, la guida ecografica rende il BPC intermedio una tecnica sicura e facile da eseguire. L’apprendimento della tecnica anestetica e necessario per ridurre il rischio di sviluppare complicanze. Le complicanze sono principalmente correlate alla puntura vascolare, a un’iniezione peri- o intradurale e alla tossicita degli anestetici locali il cui assorbimento plasmatico e intenso in questa zona.

Published
2017
Full Text
View/download PDF

48. Bloqueo del plexo cervical

Author

L Ley-Ghiglione, J P Guerin, F Bonnet, I Rouquette-Vincenti, and A Theissen

Subjects
Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, 030202 anesthesiology, business.industry, medicine, 030230 surgery, business, Humanities
Published
2017
Full Text
View/download PDF

49. Robot-assisted third duodenum resection for villous tumor (with video)

Author

A. Camerlo, C. Vanbrugghe, and F. Bonnet

Subjects
Adenoma, Adult, medicine.medical_specialty, business.industry, Colonoscopy, General Medicine, Resection, Surgery, Mini invasive surgery, medicine.anatomical_structure, Robotic Surgical Procedures, Duodenal Neoplasms, Duodenum, medicine, Humans, Robot, Robotic surgery, business, Duodenoscopy
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results